| Drug Type Antibody drug conjugate (ADC) | 
| Synonyms- | 
| Target | 
| Action antagonists, inhibitors | 
| Mechanism HER2 antagonists(Receptor tyrosine-protein kinase erbB-2 antagonists), Tubulin inhibitors | 
| Therapeutic Areas | 
| Active Indication | 
| Inactive Indication- | 
| Originator Organization | 
| Active Organization | 
| Inactive Organization- | 
| License Organization- | 
| Drug Highest PhasePreclinical | 
| First Approval Date- | 
| Regulation- | 
| Molecular FormulaC39H62N6O5S | 
| InChIKeyVNKVPXRCRUDPAH-JYZGKHMWSA-N | 
| CAS Registry- | 

| Indication | Highest Phase | Country/Location | Organization | Date | 
|---|---|---|---|---|
| Neoplasms | Preclinical | United States  | 17 Apr 2024 | 






